1	The prevalence of cardiovascular disease risk factors among adults living in
2	extreme poverty: a cross-sectional analysis of 105 nationally representative
3	surveys with 33 million participants
4	Authors: Pascal Geldsetzer ^{1,2} †*, Rebecca L. Tisdale ^{3,4} †, Lisa Stehr ⁵ , Felix Michalik ^{1,5} , Julia Lemp ⁵ , Krishna K. Aryal ⁶ , Albertino Damasceno ⁷ , Corine Houehanou ⁸ , Jutta Mari Adelin
5 6	$Iargensen^9$ Nuno Lunet ⁷ Mary Mayige ¹⁰ Sahar Saeedi Moghaddam ¹¹ Iosenh Kihachio
7	Mwangi ¹² , Christian Bommer ^{5,13} , Maja-Emilia Marcus ^{13,14} , Michaela Theilmann ⁵ , Rifat
8 9	Mwangi ¹² , Christian Bommer ^{5,13} , Maja-Emilia Marcus ^{13,14} , Michaela Theilmann ⁵ , Rifat Atun ^{15,16} , Justine Ina Davies ^{17,18,19} , David Flood ²⁰ , Jennifer Manne-Goehler ^{21,22} , Jacqueline Seiglie ^{23,24} , Till Bärnighausen ^{5,25} ‡, Sebastian Vollmer ^{13,14} ‡
10	Affiliations:
11 12	¹ Department of Medicine, Division of Primary Care and Population Health, Stanford University School of Medicine; Stanford, CA, USA
13	² Chan Zuckerberg Biohub; San Francisco, CA, USA
14	³ Veterans Affairs Palo Alto Health Care System; Palo Alto, CA, USA
15	⁴ Department of Health Policy, Stanford University School of Medicine, and Center for
16 17	Health Policy, Freeman Spogli Institute for International Studies, Stanford University; Stanford, CA, USA
17	
18 19	⁵ Heidelberg Institute of Global Health, Faculty of Medicine and University Hospital, Heidelberg University, Heidelberg, Germany
20 21	⁶ Department for International Development/Nepal Health Sector Programme 3/Monitoring Evaluation and Operational Research, Abt Associates, Kathmandu, Nepal
22 23	⁷ Department of Public and Forensic Health Sciences and Medical Education, Faculty of Medicine, University of Porto, Porto, Portugal
24 25	⁸ Laboratory of Epidemiology of Chronic and Neurological Diseases, Faculty of Health Sciences, University of Abomey-Calavi, Cotonou, Benin
26 27	⁹ Institute of Global Health, Dept of Public Health and Epidemiology, Copenhagen University, Denmark
28	¹⁰ National Institute for Medical Research, Dar es Salaam, Tanzania
29 30	¹¹ Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
31	¹² Division of Non-Communicable Diseases, Ministry of Health, Nairobi, Kenya
32	¹³ Centre for Modern Indian Studies, University of Goettingen, Göttingen, Germany
33	¹⁴ Department of Economics, University of Goettingen, Göttingen, Germany
34	¹⁵ Department of Global Health and Population, Harvard T. H. Chan School of Public Health,
35	Boston, MA, USA
36	¹⁶ Department of Global Health and Social Medicine, Harvard Medical School, Harvard
37	University, Boston, MA, USA

1 2	¹⁷ Institute of Applied Health Research, University of Birmingham, Birmingham, United Kingdom
3 4	¹⁸ MRC/Wits Rural Public Health and Health Transitions Research Unit, School of Public Health, University of the Witwatersrand, Johannesburg, South Africa
5 6	¹⁹ Centre for Global Surgery, Department of Global Health, Stellenbosch University, Cape Town, South Africa
7	²⁰ University of Michigan, Ann Arbor, MI, USA
8	²¹ Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA
9 10	²² Medical Practice Evaluation Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
11	²³ Diabetes Unit, Massachusetts General Hospital, Boston, MA, USA
12	²⁴ Department of Medicine, Harvard Medical School, Boston, MA, USA
13	²⁵ Harvard Center for Population and Development Studies, Cambridge, MA, USA
14	
15	*Corresponding author. Email: pgeldsetzer @stanford.edu
16	
17	†These authors contributed equally to this work and share first authorship.
18	‡These authors contributed equally to this work and share senior authorship.
19 20	

1 Abstract

- Background: Historically, the international development community has often held the view
 that those living in extreme poverty (at less than \$1.90/day) are likely to have a low prevalence
- 4 of cardiovascular disease (CVD) risk factors due to calorie scarcity, a largely plant-based diet,
- 5 and physical labor. Evidence on CVD risk factor prevalence among adults living below the
- 6 World Bank's international line for extreme poverty globally is sparse because studies have used
- 7 measures of socioeconomic status that are not comparable across study populations and
- countries. For adults living in extreme poverty, this study aimed to determine i) the prevalence of
 each of five key CVD risk factors, ii) how the prevalence of these CVD risk factors varies across
 and within countries, and iii) the level of treatment coverage with statin, antihypertensive, and
- 11 diabetes therapy.
- Methods: We pooled individual-level data from 105 nationally representative household surveys with physical measurements of hypertension, diabetes, overweight, obesity, and dyslipidemia, as
- 14 well as self-reported smoking status, from 78 countries that represent 85% of people living in
- 15 extreme poverty globally. Those living in extreme poverty were defined by ordering participants
- according to a continuous household wealth index or household income value, and then applying
- 17 World Bank estimates on the proportion of each country's population that is living in extreme
- poverty. We used modified Poisson regression models to examine how CVD risk factor
 prevalence among those in extreme poverty varied by age, sex, educational attainment, and rural
- versus urban residency. We also calculated the proportion of participants with diabetes or
 hypertension who self-reported the use of blood pressure- or blood glucose-lowering medication,
 respectively; the proportion with hypertension who achieved blood pressure control; and the
 proportion recommended for statin use according to WHO guidelines who reported taking a
- 24 statin.
- **Results:** Of 32,695,579 participants, 7,922,289 were living in extreme poverty (<\$1.90 per day),
 15,986,099 on less than \$3.20/day, and 23,466,879 on less than \$5.50/day. Among those living
 in extreme poverty (<\$1.90 per day), the age-standardized prevalence was 17.5% (95% CI:
- 28 16.7% 18.3%) for hypertension, 4.0% (95% CI: 3.6% 4.5%) for diabetes, 10.6% (95% CI:
- 29 9.0% 12.3%) for current smoking, 3.1% (95% CI: 2.8% 3.3%) for obesity, and 1.4% (95%
- 30 CI: 0.9% 1.9%) for dyslipidemia. In most countries in our analysis, the prevalence of these risk
- factors among those living in extreme poverty was not notably lower than in the total population.
 Hypertension treatment and control, diabetes treatment, and statin use were low across all
- poverty levels in low-income countries, while in lower and upper middle-income countries
 individuals living at more extreme levels of poverty had a lower probability of reporting the use
- 35 of these medications and achieving hypertension control.
- 36 **Conclusions:** We found a high prevalence of CVD risk factors among adults living below the
- 37 World Bank's international line for extreme poverty, along with low statin use and low treatment
- rates for diabetes and hypertension. Our detailed analysis and comparison across poverty levels
- 39 could inform equity discussions for resource allocation and the design of effective interventions.
- 40

1 Background

- 2 The prevalence of cardiovascular disease (CVD) risk factors among those living in extreme
- 3 poverty in low- and middle-income countries (LMICs) has often been assumed to be low 1,2 .
- 4 Historically, this subpopulation has been thought to take in fewer calories and have
- 5 correspondingly lower body mass index $^{3-7}$, consume a largely plant-based diet $^{3,7-11}$ and earn
- 6 income through occupations associated with higher physical activity ^{3,6,12,13}. All of these lifestyle 7 patterns decrease the risk of developing CVD and its risk factors ¹⁴.
- Understanding the extent to which this assumption of a low prevalence of CVD risk factors 8 among those in extreme poverty holds true is important for setting priorities within health policy 9 10 and care delivery, both for equity and effectiveness. From an equity perspective, if CVD risk factors mostly affect wealthier population groups in LMICs, then investing in programs aimed at 11 preventing and treating CVD instead of focusing on those conditions that disproportionately 12 affect those in extreme poverty could further worsen health inequalities by wealth. Regarding 13 14 effectiveness, understanding the prevalence of CVD risk factors in different population groups is 15 essential for the tailoring of appropriate interventions. For instance, if the prevalence of treatable CVD risk factors, such as diabetes and hypertension, is high among those living in extreme 16 17 poverty but their engagement with the healthcare system for these conditions is low, then programs that identify ways to engage this population in screening and long-term care for these 18 conditions will be needed. 19
- Despite the importance of this information for guiding health policy and healthcare delivery, to 20 date little data from nationally representative surveys on CVD risk factor prevalence among 21 adults living in extreme poverty exist ^{15,16}. The few studies that do exist employ one of two types 22 of measures of poverty. A subset of the literature relies on relative measures of poverty, 23 particularly household wealth quintiles ^{15,16} or tertiles ^{17,18}. These measures are specific to the 24 population in which they are calculated because they are relative categories (i.e., the absolute 25 difference in the degree of poverty between a given set of household wealth quintiles will vary 26 across populations) and based on dwelling characteristics and household ownership of durable 27 goods that are inherently context-specific¹⁹. They, thus, have limited value in informing CVD 28 risk factor prevalence among those living below an absolute threshold of poverty, such as the 29 World Bank's international poverty line for extreme poverty 20 . A second body of literature uses educational attainment as a measure of poverty $^{15-17,21-23}$. This approach has two critical 30 31 limitations. First and foremost, education is an imperfect proxy for poverty. For instance, a given 32 individual's education is unlikely to change later in life 2^{4} , yet that individual's economic status 33 could change significantly over the decades after leaving school. Second, quality of education 34 varies widely across and within countries in LMICs^{25,26}, such that years of schooling or a given 35 school degree hold little information outside of specific settings. 36
- This study overcomes these limitations of sparse nationally representative data and poverty 37 measures that are not comparable across settings. We have brought together and harmonized 105 38 nationally representative surveys with (except for smoking) physical measurements on five 39 major CVD risk factors (diabetes, dyslipidemia, hypertension, obesity, and smoking) from 78 40 LMICs. This is by far the largest and most comprehensive analysis of the relationship between 41 poverty and CVD risk factors to date. The countries included in our dataset are estimated to be 42 home to 85% of individuals living in extreme poverty worldwide ^{27,28}, and represent 53% of the 43 global population as well as 64% of the global population living in LMICs²⁸. By harnessing the 44 national representativeness of our data, we employ a consistent definition of extreme poverty 45 across countries such that we are, for the first time, able to provide estimates of CVD risk factor 46

prevalence among adults living in extreme poverty globally. Specifically, for adults living in extreme poverty in our study countries, this study aimed to determine i) the prevalence of each of five key CVD risk factors (and how these prevalence estimates compare to population groups with higher levels of income), ii) how the prevalence of these CVD risk factors varies across and within countries, and iii) the level of treatment coverage with statin, antihypertensive, and diabetes therapy.

6 7

8 Methods

9 Data sources

To identify relevant surveys, we first searched the Stepwise Approach to Surveillance (STEPS) 10 11 database of the World Health Organization (WHO) and systematically searched for surveys conducted by the Demographic and Health Surveys (DHS) program and the WHO Global Adult 12 Tobacco Survey (GATS) initiative (Supplementary Materials and Methods 1). STEPS, DHS, and 13 GATS surveys each utilize standardized questionnaires. Our search was limited to countries 14 designated LMICs at the time of data collection based on the World Bank income classification 15 29 . For inclusion, we required that surveys: (1) be conducted during or after 2005; (2) be 16 nationally representative with a response rate >50%; (3) provide individual-level data; (4) 17 measured at least one of the following risk factors using the measure in parentheses: 18 hypertension (blood pressure), diabetes (fasting blood glucose or HbA1c), overweight/obesity 19 20 (height, weight), smoking (self-report via questionnaire), or dyslipidemia (total or LDL cholesterol); and (5) include a measurement of household income (self-reported household 21 income or a household wealth index based on questionnaire responses to a household's 22 23 ownership of selected assets, materials used for housing construction, and types of water access and sanitation facilities) (Supplementary Materials and Methods 1). If an eligible STEPS, DHS, 24 or GATS dataset was not available for an LMIC, or we could not gain access to the individual-25 level data, we conducted a systematic search with Google to identify eligible surveys for the 26 given country (Supplementary Materials and Methods 1). 27

Our search returned 54 STEPS surveys, 103 DHS surveys, 30 GATS surveys, and 9 surveys via the Google search that met our inclusion criteria. When more than one survey measured a CVD risk factor in a given country, we used the survey that was conducted more recently for that CVD risk factor. If survey collection years were identical, we used the survey that sampled a wider age range of participants. Through this process (detailed in Figures S1-S4), we arrived at a total of 105 surveys for our analysis, of which 36 were STEPS surveys, 51 DHS surveys, 12 GATS surveys and six other types of surveys.

- The sampling strategy used by each survey included in our analysis is detailed in Supplementary Materials and Methods 2.
- 37

38 **Definition of poverty**

The World Bank publishes annual data on the estimated proportion of the population in each country that is living below each of three poverty lines, defined by an income (all in 2011 purchasing-power-parity [PPP] adjusted dollars) of \$1.90 per day (the "international poverty line"), \$3.20 per day, and \$5.50 per day²⁰. Our analysis focuses on those living in extreme poverty, which is generally defined by the international poverty line of \$1.90 per day²⁰.

- However, to enable comparison with other income groups in LMICs, we also examine the
 prevalence of CVD risk factors for the population with an income below each \$3.20 and \$5.50
 per day, as well as those with an income greater than \$5.50 per day. For simplicity, we refer to
 these categorizations as "poverty levels".
- 5 Sixty-seven surveys included a continuous household wealth index. This index was computed 6 from a principal component analysis of participants' answers to questions on key household 7 dwelling characteristics and household ownership of durable goods (i.e., goods that are not 8 completely consumed in one use). Most STEPS surveys instead asked participants for their 9 household's income, allowing participants to provide the income as a yearly, monthly, or weekly 10 figure.
- Given that the surveys included in our analysis were all nationally representative, we used the 11 distribution of household wealth or income in each survey dataset to define which participants 12 fell below each poverty level. Specifically, we first ordered participants in each dataset from 13 14 "poorest" to "richest" by their value of the (continuous) household wealth index or income. We then used the World Bank's estimate for the proportion of the population in the given country 15 (for the year of the survey's data collection) that fell below each poverty level (the "poverty 16 headcount ratio") to select a given proportion (after applying sampling weights) of the 17 participants with the lowest household wealth or income values. For example, in a dataset with 18 5,000 participants for a country with a poverty headcount ratio of 10% for extreme poverty 19 (\$1.90 per day) in the year of the survey's data collection, we determined that the 500 20 participants with the lowest household wealth or income value were living in extreme poverty. 21 22 Details on the household wealth and income measures available in each survey, and our calculation to assign a poverty level to each participant, are provided in Table S13 and 23 24 Supplementary Materials and Methods 5.4.
- 25

26 Definition of CVD risk factors and statin use

27 Hypertension

Of the 50 surveys that we used to estimate hypertension prevalence, 37 surveys used a digital 28 29 upper arm meter for blood pressure (BP) measurements, one survey a digital wrist meter, and one a manual mercury sphygmomanometer (Supplementary Materials and Methods 3.1, Table 30 31 S2). For 11 countries, the BP measurement device was not stated in the survey documentation. BP was measured three times in 46 countries, three countries undertook two measurements, and 32 one country measured twice inducing a third measurement if the first two differed by more than 33 10 mmHg. Based on established usage in LMICs and following the recommendations of the 34 35 International Society of Hypertension, we defined hypertension as systolic BP \geq 140 mmHg, diastolic BP \geq 90 mmHg, or reporting to be taking medication to lower BP ³⁰. If three BP 36 measurements were available, the mean of the last two was employed, and averages were used 37 for surveys with two measurements. 38

39

40 Diabetes

41 Of the 42 surveys that we used to estimate diabetes prevalence, 30 surveys used a point-of-care

- 42 fasting capillary glucose measurement, three surveys used a laboratory-based assessment of
- 43 fasting plasma glucose, and nine surveys measured HbA1c (Supplementary Materials and
- 44 Methods 3.2, Table S3). Following clinical lab standards and published guidelines ³¹, we used

- plasma equivalents for our analysis by multiplying capillary glucose values by 1.11 in those
 eight surveys that did not provide plasma equivalents. Based on the WHO diagnostic criteria,
 respondents were diagnosed with diabetes if they had either (1) a fasting plasma glucose of 7.0
 mmol/l (126 mg/dl) or higher, (2) a plasma glucose of 11.1 mmol/l (200 mg/dl) or higher with no
 fasting, (3) HbA1c records of 6.5% or higher, or (4) reported to take medication for diabetes ³².
 In the 17 surveys for which information on fasting status was missing, we assumed participants
 to be fasting, thereby complying with the fasting instructions that were given in all surveys.
- 8

9 Overweight and obesity

Height and weight were measured by trained personnel in all 72 surveys that we used to estimate overweight and obesity prevalence. Details on height and weight measurements for each survey are given in Supplementary Materials and Methods 3.3, and Table S4. Following WHO classifications, we defined overweight as a body mass index (BMI) of 25.0 to $<30.0 \text{ kg/m}^2$ and obesity as a BMI $\ge 30.0 \square \text{kg/m}^{2.33}$.

16 Smoking

In the 73 surveys that we used to estimate smoking prevalence, we defined current smoking as stating to be a current smoker of cigarettes or other smoked tobacco products. The specific questions used to define smoking in each survey are detailed in Supplementary Materials and Methods 3.4. and Table S5.

21

15

22 Dyslipidemia

Cholesterol measurements were taken using point-of-care devices (see Supplementary Materials 23 and Methods 3.5 and Table S6 for details). We used total cholesterol and low-density lipoprotein 24 (LDL) to determine dyslipidemia. Of the 32 surveys that we used to estimate dyslipidemia 25 prevalence, five had measured both total and LDL cholesterol while the remaining 27 surveys 26 only measured total cholesterol. In the 27 surveys that did not measure LDL but did measure 27 total cholesterol, triglycerides, and high-density lipoprotein (HDL), we used the Friedewald 28 equation to estimate LDL for each participant ³⁴. Following the National Cholesterol Education 29 Program's Adult Treatment Panel III (ATP III) guidelines³⁵, we defined dyslipidemia as (1) 30 having a total cholesterol above 240 mg/dL, (2) self-reporting the use of lipid-lowering 31 medication, or (3) having an LDL higher than 160 mg/dL. More details on the measurement of 32 blood lipids and definition of dyslipidemia in each survey are provided in Supplementary 33 34 Materials and Methods 3.5. and 5.1.

- 35
- 36 Statin use

Nineteen surveys collected data on statin use. The questions used to determine statin use and
 CVD history in each survey are detailed in Supplementary Materials and Methods 3.8.

- 39
- 40 Statistical analysis

- 1 We used age-standardized sampling weights for all prevalence estimates, weighting to the age 2 structure of the WHO standard reference population ³⁶. When providing estimates across all
- included countries, by World Bank country income group, or by world region, we additionally
- 4 weighted countries, by world bank country income group, or by world region, we additionary
- 5 poverty level who reside in the given country (as estimated using the World Bank's poverty
- 6 headcount ratio and the United Nation's population size estimates ^{27,37}). All analyses were
- 7 restricted to non-pregnant participants aged 15 years or older.
- 8 Our analysis had four steps. First, we estimated the prevalence of each CVD risk factor by 9 poverty level (income<\$1.90/day, <\$3.20/day, <\$5.50/day, >\$5.50/day, or total population) and 10 World Bank country income group in the year of the survey's data collection (low-income, lower 11 middle-income, or upper middle-income)²⁹.
- 12 Second, to determine how the prevalence of each CVD risk factor varied by individual-level
- 13 characteristics among those living in extreme poverty, we regressed each CVD risk factor onto
- age, sex, educational attainment, and rural versus urban residency (both jointly in covariate-
- adjusted regression and separately in covariate-unadjusted regressions). We used Poisson
- regression models with a robust error structure, country-level fixed effects, and restricted cubic splines with five knots for age (placed at the 5^{th} , 27.5^{th} , 50^{th} , 72.5^{th} , and 95^{th} percentile).
- Education was categorized as "no formal schooling", "primary education" (≤ grade 6), and
 "secondary education (grade 7 to 12) or further", using local education classifications whenever
 available, and years of education in cases where categorical variables were unavailable. More
 detail on the creation of the education variable is provided in Supplementary Materials and
 Methods 4 and Tables S10-S11. Standard errors were adjusted for clustering at the level of the
 primary sampling unit (usually a village or neighborhood) and household.
- Third, we examined how the prevalence of each CVD risk factor among those living in extreme 24 poverty varied by a country's level of economic development (as estimated using GDP per capita 25 in the year of the survey's data collection 38) and a country's "poverty intensity". We use the 26 term "poverty intensity" in this manuscript to refer to the mean daily income (in 2011 PPP-27 adjusted dollars) among those living in extreme poverty, as estimated by the World Bank for the 28 year of the survey's data collection ³⁹. It is, thus, a measure of the depth of poverty among those 29 below the poverty line of \$1.90 per day. To do so, we plotted the prevalence of each CVD risk 30 factor in a country against the country's GDP per capita and the country's poverty intensity 31 among those living in extreme poverty. 32
- Fourth, to ascertain the level of treatment coverage for CVD risk reduction among those living in 33 extreme poverty, we calculated the proportion of participants that self-reported the use of 34 medication to lower BP or blood glucose levels among those with hypertension and diabetes, 35 respectively. In addition, among those with hypertension who reported to be taking BP-lowering 36 37 medication, we computed the proportion that had a systolic BP <140 mmHg and a diastolic BP <90 mmHg (henceforth referred to as "controlled hypertension"). Lastly, we calculated treatment 38 coverage with statin medication following the WHO guidelines for recommended statin use 40 . 39 40 To do so, we computed the proportion of participants: i) with a history of CVD (see Supplementary Materials and Methods 3.8 for the questions used in each survey to ascertain 41 CVD history) who reported to be taking a statin medication (statin use for secondary prevention), 42 43 and ii) who were 40 years or older with either a diagnosis of diabetes or a ten-year CVD risk greater than 20% (as per the 2019 WHO laboratory-based risk equations ⁴¹; statin use for primary 44 prevention). More detail on the analyses for this fourth step is provided in Supplementary 45 Materials and Methods 5.3. 46

- This analysis was considered exempt for not-human-subjects research by the institutional review
 boards at the Stanford University School of Medicine and the Heidelberg University Medical
 Faculty.
- 4

5 Data availability

This study includes individual-level data from 105 surveys. Data are publicly available for 102
of these surveys. For data that are not publicly accessible and for which we have arranged
specific data-use agreements, we are unable to share these data given the terms of our
agreements. All data management and analysis code will be posted in a public repository upon
acceptance of the manuscript.

11

12 **Results**

13 Sample characteristics

14 Our analysis included 105 surveys with a total sample size of 32,695,579 participants (**Table 1**).

15 The survey-level median age of participants was 35.0 years with a survey-level interquartile

range of 32.0 to 39.0 years. Of these 32,695,579 participants, 7,922,289 were living in extreme poverty (<\$1.90 per day), 15,986,099 on less than \$3.20/day, and 23,466,879 on less than

5.50/day. The median survey response rate was 96.3%, ranging from 91.0% to 98.8%.

19

20 Prevalence of CVD risk factors among adults living in extreme poverty

Across all our study countries, the age-standardized prevalence of each CVD risk factor among those living in extreme poverty (<\$1.90 per day) was 17.5% (95% CI: 16.7% – 18.3%) for hypertension, 4.0% (95% CI: 3.6% – 4.5%) for diabetes, 10.6% (95% CI: 9.0% – 12.3%) for current smoking, 3.1% (95% CI: 2.8% – 3.3%) for obesity, and 1.4% (95% CI: 0.9% – 1.9%) for dyslipidemia (Table S14).

Stratified by World Bank country income category, Figure 1 compares the prevalence of each 26 CVD risk factor among those living in extreme poverty (<\$1.90 per day) to the prevalence 27 among the entire population, as well as those living below \$3.20 per day, below \$5.50 per day, 28 and above \$5.50 per day. With the exception of current smoking, obesity, and dyslipidemia in 29 lower middle-income countries, the prevalence of each CVD risk factor among those living in 30 extreme poverty (<\$1.90 per day) was not notably lower than in the total population, and 31 frequently even exceeded the prevalence in the total population. The prevalence of *hypertension* 32 was above ten percent among each population income group in Figure 1 in low-income, lower 33 middle-income, and upper middle-income countries, with relative differences between these 34 population groups being comparatively small. Similarly, differences in the prevalence of 35 *diabetes* across population income groups did not exceed six percentage points. A clear gradient 36 wherein those with higher incomes had a higher prevalence of diabetes was only apparent in 37 lower middle-income countries. The prevalence of *current smoking* was low across population 38 income groups in low-income countries, and high across population income groups in upper 39 middle-income countries. As for diabetes, we observed an income gradient in the prevalence of 40 41 current smoking in lower middle-income countries wherein individuals with higher incomes were more likely to smoke. The prevalence of *obesity* displayed a similarly positive income 42 gradient across all World Bank country categories. The prevalence of dyslipidemia was below 43

- three percent among each population income group in low-income countries and above ten
 percent among each population income group in upper middle-income countries. In lower
 middle-income countries, the prevalence of dyslipidemia had a strong positive income gradient.
- 4

5 Variation in CVD risk factor prevalence among those living in extreme poverty by sex, 6 education, and rural-urban residency

Among participants living in extreme poverty, only diabetes was associated with differential 7 prevalence by rurality, with urban dwellers at higher risk (RR: 1.47 [95% CI: 1.08 – 2.00]) 8 (Figure 2). When stratifying those living in extreme poverty by sex, men had a slightly higher 9 10 prevalence of hypertension (RR: 1.09 [95% CI: 1.01 - 1.17]), a substantially lower prevalence of obesity (RR: 0.36 [95% CI: 0.24 - 0.54]), and a far higher prevalence of smoking (RR: 13.1611 12 [95% CI: 10.37 – 16.70]) than women. No significant differences in CVD risk factor prevalence 13 were seen by education level except for smoking, which was more common among those in extreme poverty with a high school education or above compared to those with no schooling 14 (RR: 1.45 [95% CI: 1.22 - 1.74]). 15

16

Association of CVD risk factor prevalence among those living in extreme poverty with a country's economic development and intensity of poverty

19 The prevalence of overweight and obesity among those living in extreme poverty (<\$1.90 per day) was positively associated with a country's level of economic development (GDP per capita) 20 as well as the mean daily income of those living in extreme poverty in a country (i.e., the less 21 "intense" the mean level of poverty among those living in extreme poverty in a country, the 22 higher was the prevalence of overweight and obesity among those living in extreme poverty) 23 (Figure 3). A country's economic development and poverty intensity was not significantly 24 25 correlated with the prevalence of hypertension and diabetes among those living in extreme poverty. Current smoking was positively associated with a country's mean daily income among 26 those living in extreme poverty. Analogous analyses as in Figure 3, but for those living below 27 \$3.20 per day and \$5.50 per day, are shown in Figures S11-S13, and demonstrated similar 28 29 patterns.

30

31 Treatment of CVD risk among those living in extreme poverty

Among those living in extreme poverty (<\$1.90/day) who had hypertension, 15.2% (95% CI: 32 13.3% - 17.1%) reported taking BP-lowering medication and 5.7% (95% CI: 4.7% - 6.7%) had 33 achieved hypertension control (i.e., systolic BP <140 mmHg and diastolic BP <90 mmHg). 34 19.7% (95% CI: 15.3% - 24.1%) of those living in extreme poverty (<\$1.90/day) with diabetes 35 reported taking blood glucose-lowering medication. Among those living in extreme poverty 36 (<\$1.90/day) who should be taking a statin for secondary prevention of CVD according to WHO 37 guidelines, only 1.1% (95% CI: 0.4% – 1.9%) were doing so. In low-income countries, 38 hypertension treatment and control, diabetes treatment, and statin use were low among each 39 poverty level (Figure 4). In lower middle-income countries, individuals living at more extreme 40 levels of poverty had a consistently lower probability of being on treatment for their 41 hypertension and diabetes, achieving hypertension control, and using statins for primary or 42 43 secondary prevention of CVD. These gradients by poverty level were less pronounced in upper

- middle-income countries, where instead the difference between those at any poverty level of less
 than <\$5.50/day versus living on >\$5.50/day tended to be the largest.
- 3

4 Discussion

Our analysis of nationally representative survey data on CVD risk factors from 78 LMICs that are home to the vast majority (an estimated 85% ^{27,28}) of individuals living in extreme poverty 5 6 globally generally found a high prevalence of CVD risk factors among this population group. In 7 fact, in most countries included in our analysis, the prevalence of these risk factors among those 8 9 living in extreme poverty was not notably lower than in the total population. Our findings thus contradict the common assumption that the environment (e.g., food scarcity $^{3-7}$) and lifestyles 10 (e.g., more physical labor 3,6,12,13) of those living in extreme poverty in LMICs results in a 11 minimal prevalence of CVD risk factors among this group. At the same time, we find marked 12 positive income gradients in rates of evidence-based treatment for these conditions, which 13 further increases the risk of CVD events, such as myocardial infarctions and strokes, among 14 15 those in extreme poverty relative to wealthier individuals in LMICs.

In 2015, The Lancet NCDI Poverty Commission was founded in the conviction that "non-16 communicable diseases and injuries (NCDIs) are an important, yet an under-recognized and 17 poorly-understood contributor to the death and suffering" of the poorest billion in the world ⁴². 18 Focusing largely on the political, economic, and financing aspects of addressing NCDIs in 19 LMICs $\frac{42}{2}$, the commission restricted its quantitative analyses on the prevalence of NCDIs and its 20 risk factors among the poorest billion merely to data from seven Health and Demographic 21 Surveillance Sites (each representative for populations ranging in size from 31,000 to 129,000⁴³) 22 23 in five countries in sub-Saharan Africa. In what is, to our knowledge, the first study to estimate CVD risk factor prevalence among adults living in extreme poverty using multi-country 24 nationally representative data, this research thus provides a crucial empirical foundation for the 25 future work of this commission. At its inception, the commission hypothesized that NCDIs 26 among those in extreme poverty are more likely to be the result of infections and harmful 27 environments (e.g., exposure to environmental toxins) than behavioral risk factors ⁴⁴. Although 28 29 we did not examine infectious and environmental risk factors, we found a comparatively high prevalence of five major CVD risk factors, for which behavioral choices are thought to play an important causal role ^{14,45,46}, among adults in extreme poverty. 30 31

In addition to our findings on the overall prevalence of CVD risk factors among those living in 32 extreme poverty, our detailed analyses of how CVD risk factor prevalence and treatment 33 coverage vary by individual-level characteristics among this population group could inform the 34 effective targeting and tailoring of appropriate interventions and policies to reduce CVD risk in 35 this vulnerable group. However, because risk factors may not map perfectly or predictably onto 36 resultant CVD outcomes, such as because of competing risk from infectious causes of death, our 37 data are only suggestive of the CVD burden of those living in extreme poverty as compared to 38 that of wealthier population groups. They cannot on their own establish whether investments in 39 40 treating CVD risk factors in LMICs would be equitable. Nevertheless, we would like to highlight five points that we believe are important when considering the equity implications of investing in 41 reducing CVD risk in LMICs. First, we found that those living in extreme poverty in LMICs not 42 only have a high prevalence of CVD risk factors but are generally also least likely to be taking 43 CVD risk-reducing medications. Second, it is likely that this vulnerable segment of society has 44 the least access to high-quality care for CVD events in most settings ^{47,48}. Third, those living in 45

- extreme poverty experience far greater wage losses relative to their household spending from an
 illness episode (including for CVD) than do wealthier population groups ⁴⁹. Fourth, we found
- 3 that the prevalence of overweight and obesity among those living in extreme poverty are
- 4 positively associated with a country's GDP per capita and the mean daily income among those
- 5 living in extreme poverty. It is, therefore, likely that as LMICs develop economically,
- 6 overweight and obesity prevalence among the poorest segments of their societies will increase
- and, at least partially as a result of this rise in unhealthy weight, the prevalence of diabetes,
 dyslipidemia, and hypertension will also grow. Lastly, relative to its disease burden, care and
- 9 prevention for CVD, and NCDs more broadly, are currently vastly underfunded compared to
- 10 infectious diseases and maternal and child health 50,51 .
- Our study has several additional limitations. First, while the countries included in our sample 11 comprised 86% of the current global population of LMICs (as well as 85% of the global 12 population) estimated to be living in extreme poverty ^{27,37}, they are not a probabilistic subset of 13 countries but were instead selected due to their data availability. They may, thus, not fully 14 represent all LMICs or adults living in extreme poverty globally. Second, the surveys were 15 conducted in different years, limiting comparability among them (although a comparison of 16 countries was not the primary objective of our study) and generalizability to the present. They 17 do, however, constitute the most recent nationally representative data available. Third, we did 18 not have detailed consumption data for our surveys, but had to rely instead on household wealth 19 indices or data on household income to define extreme poverty. In a subset of 38 surveys in 20 which we did not have a household wealth index, we used self-reported household income to 21 22 define poverty. This is a limitation in so far as households in LMICs commonly have multiple income sources (complicating calculations for participants) and varying income between 23 different years ⁵². In addition, we were unable to adjust household income based on household 24 size in this subset of 38 surveys due to a lack of consistent information on the number of 25 household members and their age across surveys. In 19 of these 38 surveys, the survey for which 26 we had to use total household income was only used for a subset of the five CVD risk factors 27 28 examined in this analysis. Fourth, we did not have sufficiently detailed and homogeneous data to be able to use multi-dimensional measures of poverty, such as the multi-dimensional poverty 29 index ⁵³. Fifth, hypertension and diabetes were assessed in one-off measurements rather than the 30 multiple measurements that are generally recommended for a clinical diagnosis of these 31 conditions ^{54,55}. Lastly, although the primary objective of our analysis was not to compare 32 countries (or surveys) with each other, it is possible that the variation in the questionnaires and 33 34 methodology for measuring hypertension, diabetes, and dyslipidemia across our surveys introduced some level of bias in our analyses of how CVD risk factor prevalence among those 35 living in extreme poverty is associated with countries' GDP per capita and poverty intensity. 36 37 However, the three main sources of data used in this analysis (the DHS, STEPS, and GATS) each used a standardized questionnaire and approach to measuring CVD risk factors. 38
- In sum, this study demonstrates that CVD risk factors affect individuals across the full 39 socioeconomic spectrum, including those living in extreme poverty, within countries at all levels 40 of economic development. Although we did not directly assess CVD morbidity and mortality nor 41 the disease burden from non-CVD causes, our findings of a high CVD risk factor prevalence 42 along with a low coverage with CVD risk-reducing medications among those living in extreme 43 poverty suggest that equity concerns are likely misplaced in justifying the current vast 44 underfunding of CVD prevention and care compared to other health areas in LMICs ^{50,51}. Our 45 unique effort of collating nationally representative data on CVD risk factors from 78 LMICs and 46

- applying a consistent definition of poverty across surveys can inform not only resource allocation decisions but also the design of appropriate preventive or care interventions.

References

- 1. Zuccala, E. & Horton, R. Reframing the NCD agenda: a matter of justice and equity. *The Lancet* **396**, 939–940 (2020).
- 2. Yach, D., Hawkes, C., Gould, C. L. & Hofman, K. J. The global burden of chronic diseases: overcoming impediments to prevention and control. *JAMA* **291**, 2616–2622 (2004).
- 3. Banerjee, A. V. & Duflo, E. The economic lives of the poor. *Journal of Economic Perspectives* **21**, 141–68 (2007).
- 4. Subramanian, S. & Deaton, A. The Demand for Food and Calories. *Journal of Political Economy* **104**, 133–162 (1996).
- 5. U, A., Akhter *et al. The world's most deprived: Characteristics and causes of extreme poverty and hunger.* (Intl Food Policy Res Inst, 2007).
- 6. Hickel, J. The true extent of global poverty and hunger: questioning the good news narrative of the Millennium Development Goals. *Third World Quarterly* **37**, 749–767 (2016).
- 7. Svedberg, P. *Poverty and Undernutrition: Theory, Measurement, and Policy*. (Oxford University Press, 2000).
- 8. Wanyama, R. N. Food Security and Dietary Patterns among the Urban Poor in Africa. (2019) doi:10.53846/goediss-7447.
- 9. Hassen, I. W., Dereje, M., Minten, B. & Hirvonen, K. Diet transformation in Africa: The case of Ethiopia. *International Food Policy Research Institute* (2016).
- 10. Our World in Data. Daily meat consumption per person. *Our World in Data* https://ourworldindata.org/grapher/daily-meat-consumption-per-person.
- 11. Our World in Data. Share of energy from cereals, roots, and tubers vs. GDP per capita. *Our World in Data* https://ourworldindata.org/grapher/share-of-energy-from-cereals-roots-and-tubers-vs-gdp-per-capita.
- 12. Gindling, T. H. & Newhouse, D. Self-Employment in the Developing World. *World Development* 56, 313–331 (2014).
- 13. Collins, D., Morduch, J., Rutherford, S. & Ruthven, O. *Portfolios of the Poor: How the World's Poor Live on \$2 a Day. Portfolios of the Poor* (Princeton University Press, 2009). doi:10.1515/9781400829965.
- 14. Roth, G. A. *et al.* Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: Update From the GBD 2019 Study. *Journal of the American College of Cardiology* 76, 2982–3021 (2020).
- 15. Allen, L. *et al.* Socioeconomic status and non-communicable disease behavioural risk factors in low-income and lower-middle-income countries: a systematic review. *The Lancet Global Health* **5**, e277–e289 (2017).
- 16. Williams, J. *et al.* A systematic review of associations between non-communicable diseases and socioeconomic status within low- and lower-middle-income countries. *J Glob Health* **8**,
- 17. Rosengren, A. *et al.* Socioeconomic status and risk of cardiovascular disease in 20 lowincome, middle-income, and high-income countries: the Prospective Urban Rural Epidemiologic (PURE) study. *The Lancet Global Health* **7**, e748–e760 (2019).
- 41 18. Gupta, R. *et al.* Socioeconomic factors and use of secondary preventive therapies for
 42 cardiovascular diseases in South Asia: The PURE study. *Eur J Prev Cardiolog* 22, 1261–
 43 1271 (2015).
- 44 19. Steinert, J. I., Cluver, L. D., Melendez-Torres, G. J. & Vollmer, S. One Size Fits All? The
 45 Validity of a Composite Poverty Index Across Urban and Rural Households in South Africa.
 46 Soc Indic Res 136, 51–72 (2018).
- The World Bank. *Poverty and Shared Prosperity 2018: Piecing Together the Poverty Puzzle.* http://elibrary.worldbank.org/doi/epdf/10.1596/978-1-4648-1330-6.

- Goyal, A. *et al.* Attained Educational Level and Incident Atherothrombotic Events in Lowand Middle-Income Compared With High-Income Countries. *Circulation* 122, 1167–1175 (2010).
- 22. Yu, Z. Changes in cardiovascular risk factors in different socioeconomic groups: seven year trends in a Chinese urban population. *Journal of Epidemiology & Community Health* **54**, 692–696 (2000).
 - 23. Reddy, K. S. *et al.* Educational status and cardiovascular risk profile in Indians. *Proceedings* of the National Academy of Sciences **104**, 16263–16268 (2007).
 - 24. Shavers, V. L. Measurement of socioeconomic status in health disparities research. *J Natl Med Assoc* **99**, 1013–1023 (2007).
- 25. Fomba, B. K., Talla, D. N. D. F. & Ningaye, P. Institutional Quality and Education Quality in Developing Countries: Effects and Transmission Channels. *J Knowl Econ* (2022) doi:10.1007/s13132-021-00869-9.
- 26. Altinok, N., Angrist, N. & Patrinos, H. A. *Global Data Set on Education Quality (1965–2015)*. (World Bank, Washington, DC, 2018). doi:10.1596/1813-9450-8314.
- 27. The World Bank. Poverty headcount ratio at \$1.90 a day (2011 PPP) (% of population) | Data. *The World Bank: Data* https://data.worldbank.org/indicator/SI.POV.DDAY.
- 28. The World Bank. Population, total | Data. https://data.worldbank.org/indicator/SP.POP.TOTL.

1

2 3

4

5

6 7

8

9

10

11

12

13 14

15

16

17

18

19

20

21

22 23

24

25

26

27

28

29 30

31

32

33

34

35 36

37

38

39

40

41 42

43

- 29. The World Bank. World Bank Country and Lending Groups World Bank Data Help Desk. https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-countryand-lending-groups.
- 30. Unger, T. *et al.* 2020 International Society of Hypertension Global Hypertension Practice Guidelines. 24.
- 31. Sacks, D. B. *et al.* Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus. *Clinical Chemistry* **57**, e1–e47 (2011).
- 32. World Health Organization & International Diabetes Federation. *Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation.* (2006).
- 33. World Health Organization. WHO | Obesity: preventing and managing the global epidemic. *WHO*
 - http://www.who.int/entity/nutrition/publications/obesity/WHO_TRS_894/en/index.html.
- Friedewald, W. T., Levy, R. I. & Fredrickson, D. S. Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative Ultracentrifuge. *Clinical Chemistry* 18, 499–502 (1972).
- 35. National Institutes of Health. *National Cholesterol Education Program E. Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) -Final Report*. https://www.nhlbi.nih.gov/files/docs/resources/heart/atp-3-cholesterol-fullreport.pdf (2001).
- 36. Ahmad, O. B., Boschi-pinto, C., Lopez, A. D., Lozano, R. & Inoue, M. Age standardization of rates: a new WHO standard. in *Geneva: World Health Organization; 2000 (GPE Discussion Paper No* (2009).
- 37. United Nations Department of Economic and Social Affairs. World Population Prospects 2022. https://population.un.org/wpp/Download/Standard/Population/ (2022).
- 38. The World Bank. World Development Indicators. GDP per capita, PPP (constant 2011 international \$) [Data file]. (2020).
- 47 39. The World Bank. Poverty gap at \$1.90 a day (2011 PPP) (%) | Data.
 48 https://data.worldbank.org/indicator/SI.POV.GAPS.

40. World Health Organization. WHO package of essential noncommunicable (PEN) disease interventions for primary health care. https://www.who.int/publications-detail-redirect/who-package-of-essential-noncommunicable-(pen)-disease-interventions-for-primary-health-care.

1

2

3

4

5

6 7

8

9

10

11

12

13

14

15

16

17

18

19 20

21

22 23

24

25

26

27

28

29

30

31

32

33

34

35

36

37 38

39

- The WHO CVD Risk Chart Working Group. World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. *Lancet Glob Health* 7, e1332–e1345 (2019).
 - 42. Bukhman, G. *et al.* The Lancet NCDI Poverty Commission: bridging a gap in universal health coverage for the poorest billion. *The Lancet* **396**, 991–1044 (2020).
 - 43. MEMBER HDSSs | INDEPTH Network. http://www.indepth-network.org/member-centres.
 - 44. Bukhman, G., Mocumbi, A. O. & Horton, R. Reframing NCDs and injuries for the poorest billion: a Lancet Commission. *The Lancet* **386**, 1221–1222 (2015).
 - 45. Chomistek, A. K. *et al.* Healthy lifestyle in the primordial prevention of cardiovascular disease among young women. *J Am Coll Cardiol* **65**, 43–51 (2015).
- 46. Heath, L., Jebb, S. A., Aveyard, P. & Piernas, C. Obesity, metabolic risk and adherence to healthy lifestyle behaviours: prospective cohort study in the UK Biobank. *BMC Medicine* **20**, 65 (2022).
 - 47. Di Cesare, M. *et al.* Inequalities in non-communicable diseases and effective responses. *The Lancet* **381**, 585–597 (2013).
 - 48. Kruk, M. E. *et al.* High-quality health systems in the Sustainable Development Goals era: time for a revolution. *The Lancet Global Health* **6**, e1196–e1252 (2018).
 - 49. Srinivas, A., Jalota, S., Mahajan, A. & Miller, G. Illness and Wage Loss: Longitudinal evidence from India (and Implications for the Universal Health Coverage Agenda). 2021.11.04.21265892 Preprint at https://doi.org/10.1101/2021.11.04.21265892 (2021).
- 50. Dieleman, J. L. *et al.* Sources and Focus of Health Development Assistance, 1990–2014. *JAMA* 313, 2359–2368 (2015).
- 51. Chang, A. Y. *et al.* Past, present, and future of global health financing: a review of development assistance, government, out-of-pocket, and other private spending on health for 195 countries, 1995–2050. *The Lancet* **393**, 2233–2260 (2019).
- 52. Howe, L. D. *et al.* Measuring socio-economic position for epidemiological studies in lowand middle-income countries: a methods of measurement in epidemiology paper. *International Journal of Epidemiology* **41**, 871–886 (2012).
- 53. Oxford Poverty & Human Development Initiative & United Nations Development Programme. *Global Multidimensional Poverty Index 2021: Unmasking disparities by ethnicity, caste and gender.* https://hdr.undp.org/sites/default/files/2021_mpi_report_en.pdf (2021).
- 54. Whelton, P. K. *et al.* 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Hypertension* **71**, (2018).
- 41 55. American Diabetes Association Professional Practice Committee. 2. Classification and
 42 Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2022. *Diabetes Care* 45,
 43 S17–S38 (2021).
- 56. The World Bank. Poverty headcount ratio at \$3.20 a day (2011 PPP) (% of population) |
 Data. https://data.worldbank.org/indicator/SI.POV.LMIC.
- 46 57. The World Bank. Poverty headcount ratio at \$5.50 a day (2011 PPP) (% of population) |
 47 Data. https://data.worldbank.org/indicator/SI.POV.UMIC.

1	Acknowledgements:
2 3	We would like to thank all participants in the household surveys that have been harmonized and analyzed in this study.
4	
5	Funding:
6	Chan Zuckerberg Biohub (PG)
7 8	Veterans Affairs Office of Academic Affairs Advanced Fellowship in Health Services Research (RLT)
9 10	Alexander-von-Humboldt university professorship through the Alexander von Humboldt Foundation (TB)
11	
12	Author contributions:
13	Conceptualization: PG, TB, SV
14	Methodology: PG, LS, FM, MM, MT, TB, SV
15	Visualization: PG, RLT, LS, FM
16	Funding acquisition: PG, TB
17	Project administration: PG, RLT, LS
18	Supervision: PG
19	Writing – original draft: PG, RLT, LS
20 21	Writing – review & editing: PG, RLT, LS, FM, JL, KKA, AD, CH, JMAJ, NL, MM, SSM, KJM, MM, MT, JID, DF, JMG, JS, TB, SV
22	
23	Competing interests:
24	The authors declare that they have no competing interests.
25	
26	Materials and correspondence
27	Correspondence and materials requests should be addressed to the corresponding author (PG).
28	
29	Supplementary materials
30	Materials and Methods
31	Supplementary Text
32	Figs. S1 to S26
33	Tables S1 to S51
34 35	References

Figures

Fig. 1. Age-standardized prevalence (in percent) of CVD risk factors by poverty level in low-income, lower middle-income, and upper middle-income countries




Figure 1 depicts age-standardized prevalence of CVD risk factors for those with income <\$1.90/day,

For dyslipidemia, the upper bound of the 95% CI for those with income ≥\$5.50/day in lower middle-

income countries is 37.4%. Abbreviations: inc.=income

<\$3.20/day, <\$5.50/day, and \geq \$5.50/day for diabetes, hypertension, obesity, smoking, and dyslipidemia.






Fig. 2. Variation in CVD risk factor prevalence among those living in extreme poverty (<\$1.90/day) by rural-urban residency, sex, and education

Figure 2 depicts variation in CVD risk factors among those living in extreme poverty with stratification by rurality, sex, and level of education. The risk ratio is plotted on a logarithmic scale.





¹Regression lines in red and confidence intervals in green indicate trends that are statistically significant (p<0.05).

²The diagonal lines (in black or red) depict ordinary least-squares regressions (with each country having the same weight) of the CVD risk factor prevalence among those living in extreme poverty (<\$1.90/day) in a country onto countries' GDP per capita or mean daily income among those living on <\$1.90/day. The R² and p-values shown in the grey boxes refer to these ordinary least-squares regressions.

³The grey or green boundary depict the point-wise 95% prediction interval and the vertical bars are 95% confidence intervals around point estimates.

⁴GDP per capita and the mean daily income among those living on <\$1.90/day in a country was taken from the World Bank for the year of the survey's data collection ^{38,39}.

Abbreviations: GDP=Gross Domestic Product; int.=international. Country abbreviations: AGO=Angola; ALB=Albania; BDI=Burundi; BEN=Benin; BOL=Bolivia; BRA=Brazil; BWA=Botswana; CHN=China; COD=Congo Democratic Republic; ECU=Ecuador; EGY=Egypt; ETH=Ethiopia; GEO=Georgia;

10

5

GTM=Guatemala; HND=Honduras; IND=India; IDN=Indonesia; KEN=Kenya; KGZ=Kyrgyz Republic; KIR=Kiribati; LAO=Laos; LBR=Liberia; LSO=Lesotho; MDG=Madagascar; MEX=Mexico; MOZ=Mozambique; MWI=Malawi; NAM=Namibia; NER=Niger; PAN=Panama; PER=Peru; PHL=Philippines; RWA=Rwanda; STP=São Tomé and Principe; SLB=Solomon Islands; SWZ=Eswatini; TCD=Chad; TGO=Togo; TJK=Tajikistan; TLS=Timor-Leste; TZA=Tanzania; VNM=Vietnam; VUT=Vanuatu; ZAF=South Africa; ZMB=Zimbabwe

Figure 3 depicts associations of CVD risk factor prevalence among those living in extreme poverty (<\$1.90/day) with countries' GDP per capita and poverty intensity.




Fig. 4. Hypertension treatment and control, diabetes treatment, and statin use, by individuals' poverty level and World Bank country income group^{1,2,3}

¹Prevalences were not calculated for samples with a denominator of less than 50 individuals. This was the case for statin use for both primary and secondary prevention of CVD in low-income countries (except for the total population for secondary prevention), statin use for primary prevention of CVD among those living on <\$1.90/day in lower middle-income countries, statin use for primary prevention of CVD among those living on

<\$1.90/day and <\$3.20/day in upper middle-income countries, and statin use for secondary prevention of CVD among those living on <\$1.90/day in upper middle-income countries.

²Åll prevalence estimates are age-standardized.

³"Statin primary" and "statin secondary" refer to statin use for primary and secondary prevention of CVD, respectively.

Abbreviations: inc=income; dia=diabetes; hypt=hypertension.

Figure 4 depicts hypertension diagnosis and treatment, diabetes treatment, and statin use by poverty level and World Bank country income group.

10

Table 1	Survey	characteri	stics hy r	egion an	d county ¹	
I abic I.	Durvey	characteri	sties by I	cgron un	a county	

Country	Survey	Year ²	Response rate (%) ³	CVD risk factors	Sample size	Median age (y)	Age Range (y)	Female (%)	In extreme poverty (at <\$1.90/day) ⁴ (n, %)	In poverty at <\$3.20/day ⁴ (n, %)	In poverty at <\$5.50/day ⁴ (n, %)	Population in 2015 (thousands) ⁵	GDP per capita ⁶
East Asia a				1		ı •						· · ·	
	GATS	2010	96.0%	smoking	13354	47	15-102	50.6	1495 (11.2)	3819 (28.6)	7144 (53.5)		9498.08
China	CHNS	2009	88.0%	diabetes, hypertension, obesity, overweight	16758	41	15-105	52.8	2178 (13)	5295 (31.6)	9585 (57.2)	1371220	8626.53
Indonesia	IFLS	2014	83.0%	diabetes, hypertension, obesity, overweight, smoking	32059	36	15-110	52.3	1987 (6.2)	11156 (34.8)	21351 (66.6)	258383	10003.17
Kiribati	STEPS	2015	55.0%	diabetes, dyslipidemia, hypertension, obesity, overweight, smoking, statin use	2138	37	18-69	53.9	275 (12.9)	739 (34.6)	1483 (69.4)	110	1975.8
Lao People's Democratic Republic	STEPS	2013	99.2%	diabetes, dyslipidemia, hypertension, obesity, overweight, smoking	2484	39	16-65	59.7	342 (13.8)	1120 (45.1)	1920 (77.3)	6741	5115.6
Mongolia	STEPS	2019	98.1%	diabetes, dyslipidemia, hypertension, obesity, overweight, smoking, statin use	6368	41	18-69	54.7	31 (0.5)	254 (4)	1668 (26.2)	2998	12209.25
	DHS	2015- 2016	97.8%	obesity, overweight, smoking	36691	39	15-98	53.9	1137 (3.1)	7264 (19.8)	21354 (58.2)		5030.26
Myanmar	STEPS	2014	94.0%	diabetes, dyslipidemia, hypertension, statin use	8191	45	25-64	64.7	335 (4.1)	1859 (22.7)	4955 (60.5)	52680	4737.46

Philippines	GATS	2015	92.1%	smoking	11644	38	15-98	50.4	710 (6.1)	2992 (25.7)	6357 (54.6)	102113	6847.87
Samoa	STEPS	2013	64.0%	diabetes, dyslipidemia, hypertension, obesity, overweight, smoking	1720	39	18-64	59.6	18 (1.1)	165 (9.6)	583 (33.9)	193	5490.94
Solomon Islands	STEPS	2015	58.4%	diabetes, dyslipidemia, hypertension, obesity, overweight, smoking, statin use	2501	38	17-71	54.8	622 (24.9)	1455 (58.2)	2113 (84.5)	603	2093.50
	DHS	2016	98.6%	obesity, overweight, smoking	35776	34	15-98	50.1	6868 (19.2)	23504 (65.7)	32842 (91.8)		7566.02
Timor-Leste	STEPS	2014	96.3%	diabetes, dyslipidemia, hypertension, statin use	2555	40	18-69	57.6	562 (22)	1683 (65.9)	2345 (91.8)	1196	6466.74
Tonga	STEPS	2017	85.7%	dyslipidemia, hypertension, obesity, overweight, smoking	3782	41	18-69	63.8	34 (0.9)	283 (7.5)	1040 (27.5)	101	5745.95
Tuvalu	STEPS	2015	76.0%	diabetes, dyslipidemia, hypertension, obesity, overweight, smoking, statin use	1144	41	18-69	53.9	37 (3.3)	201 (17.6)	534 (46.7)	11	3389.01
Vanuatu	STEPS	2011	94.0%	diabetes, dyslipidemia, hypertension, obesity, overweight, smoking	4582	40	25-64	49.1	604 (13.2)	1805 (39.4)	3317 (72.4)	271	2905.90
Vietnam	GATS	2015	95.8%	smoking	8996	44	15-99	55.7	197 (2.2)	845 (9.4)	2806 (31.2)	92677	5608.47

Europe and	l Central	Asia											
Albania	DHS	2017- 2018	95.1%	obesity, overweight, smoking	43423	48	15-98	50.4	477 (1.1)	3734 (8.6)	14590 (33.6)	2880	11803.28
	DHS	2008	95.4%	hypertension	6664	33	15-49	55.0	19 (0.3)	353 (5.3)	2072 (31.1)		9154.71
Armenia	DHS	2015- 2016	96.2%	obesity, overweight, smoking	22209	46	15-95	53.5	266 (1.2)	2132 (9.6)	8328 (37.5)	2925	8158.63
Georgia	STEPS	2016	75.7%	diabetes, dyslipidemia, hypertension, obesity, overweight, smoking	4165	50	17-70	69.5	158 (3.8)	670 (16.1)	1803 (43.3)	3725	9256.15
Vumous	STEPS	2013	100%	diabetes, dyslipidemia, statin use	2550	44	25-64	62.9	56 (2.2)	543 (21.3)	1639 (64.3)		3116.61
Kyrgyz Republic	DHS	2012	96.5%	hypertension, obesity, overweight, smoking	22469	38	15-99	51.1	561 (2.5)	3842 (17.1)	14267 (63.5)	5956	2866.63
Romania	SEPH AR	2016	69.1%	diabetes, hypertension, obesity, overweight, smoking	1970	47	18-80	52.5	55 (2.8)	163 (8.3)	342 (17.4)	19815	21782.13
	DHS	2017	99·1%	obesity, overweight, smoking	28094	35	15-98	49.7	561 (2)	4466 (15.9)	12754 (45.4)		2923.67
Tajikistan	STEPS	2016	94.0%	diabetes, dyslipidemia, hypertension, statin use	2668	39	18-70	58.8	82 (3.1)	432 (16.2)	1267 (47.5)	8454	2784.68
Turkey	DHS	2013	89.9%	obesity, overweight	9029	32	15-49	100.0	27 (0.3)	243 (2.7)	966 (10.7)	78529	21610.49
Latin Amer	rica and t	he Cari	ibbean						Γ		1 1		
Bolivia	DHS	2008	98.8%	obesity, overweight, smoking	47306	35	15-99	51.2	5203 (11)	9461 (20)	18449 (39)	10869	5126.20
Brazil	PNC	2013	86.0%	hypertension, obesity, overweight, smoking	156346	38	15-109	52.2	4846 (3.1)	12351 (7.9)	30174 (19.3)	204471	15535.63

Costa Rica	GATS	2015	94·1%	smoking	8607	43	15-99	58.8	129 (1.5)	352 (4.1)	1032 (12)	4847	14617.15
Dominican Republic	DHS	2013	95.5%	obesity, overweight, smoking	27422	36	15-98	48.3	603 (2.2)	2769 (10.1)	8199 (29.9)	10281	12183.40
Ecuador	STEPS	2017- 2018	69.4%	diabetes, dyslipidemia, hypertension, obesity, overweight, smoking, statin use	4576	40	18-69	57.5	151 (3.3)	443 (9.7)	1107 (24.2)	16212	10412.20
Guatemala	DHS	2014- 2015	98.7%	obesity, overweight, smoking	62325	33	15-95	53.4	5297 (8.5)	15144 (24.3)	31037 (49.8)	16252	7292.71
Haiti	DHS	2016- 2017	99.7%	obesity, overweight, smoking	36895	34	15-98	52.8	9039 (24.5)	18558 (50.3)	28999 (78.6)	10695	1653.00
Honduras	DHS	2011- 2012	99.8%	obesity, overweight, smoking	60494	32	15-99	50.7	11493 (19)	21596 (35.7)	33997 (56.2)	9112	3984.50
	GATS	2015	82.7%	smoking	14664	40	15-104	59.7	425 (2.9)	1422 (9.7)	4237 (28.9)		17495.16
Mexico	MXFL S	2009- 2012	90.0%	diabetes, dyslipidemia, hypertension, obesity, overweight	29563	33	15-99	51.4	1241 (4.2)	3665 (12.4)	9607 (32.5)	121858	16520.26
Panama	GATS	2013	88.4%	smoking	16962	40	15-100	54.7	474 (2.8)	1373 (8.1)	3087 (18.2)	3968	19393.16
Peru	DHS	2012	94.3%	hypertension, obesity, overweight	68566	37	15-98	49.9	3291 (4.8)	8433 (12.3)	18444 (26.9)	30470	11185.81
Uruguay	GATS	2009	95.2%	smoking	5581	46	15-101	52.8	11 (0.2)	100 (1.8)	546 (9.8)	3412	15962.91
Middle Eas	t and No	rth Afri	ca										
Egypt	DHS	2015	95.0%	hypertension, smoking	14862	32	15-59	53.1	237 (1.6)	2704 (18.2)	9571 (64.4)	92442	10242.53
Lgypt	DHS	2014	98.4%	obesity, overweight	75510	34	15-98	48.0	1208 (1.6)	18197 (24.1)	53159 (70.4))2442	10032.48
Iran	STEPS	2016	98.4%	diabetes, hypertension, obesity, overweight, smoking, statin use	30109	43	18-100	51.6	120 (0.4)	933 (3.1)	4124 (13.7)	78492	18663.54
Jordan	STEPS	2019	84.0%	diabetes,	5527	38	18-69	60.1	5 (0.1)	102 (2.0)	888 (17.5)	9266	8309.30

				dyslipidemia,									
				hypertension, statin use									
	DHS	2017- 2018	98.3%	obesity, overweight, smoking	58965	32	15-95	49.0	58 (0.1)	1179 (2.0)	10318 (17.5)		8309.30
Yemen	DHS	2013	96.3%	obesity, overweight, smoking	66809	30	15-98	48.7	11424 (17.1)	33204 (49.7)	53714 (80.4)	26497	3938.89
South Asia	1								I				1
Bangladesh	DHS	2017- 2018	99.4%	diabetes, hypertension, obesity, overweight	57279	35	15-95	52.7	6873 (12)	28639 (50)	47770 (83.4)	156256	3879.16
	GATS	2017	90.8%	smoking	12783	36	15-100	52.4	1661 (13)	6544 (51.2)	10724 (83.9)		3634.32
Bhutan	STEPS	2014	96.9%	diabetes, dyslipidemia, hypertension, obesity, overweight, smoking, statin use	2753	39	17-69	61.0	52 (1.9)	374 (13.6)	1153 (41.9)	727	7954.38
	GATS	2017	92.9%	smoking	74037	37	15-110	54.4	14733 (19.9)	42053 (56.8)	63153 (85.3)		6516.17
India	DHS	2015- 2016	96.0%	diabetes, hypertension, obesity, overweight	757655	30	15-54	85.5	160622 (21.2)	440955 (58.2)	650067 (85.8)	1310	6145.29
Pakistan	DHS	2017- 2018	98.9%	obesity, overweight, smoking	60051	31	15-98	50.8	2642 (4.4)	21438 (35.7)	45758 (76.2)	199426	4927.92
Sub-Sahara	n Africa			1					1				
Angola	DHS	2015- 2016	99.4%	smoking	35624	31	15-98	53.3	16636 (46.7)	24580 (69)	31099 (87.3)	27884	6644.86
Benin	STEPS		98.6%	diabetes, dyslipidemia, hypertension, obesity, overweight, smoking, statin use	4887	36	18-69	52.4	2423 (49.6)	3723 (76.2)	4427 (90.6)	10575	1987.14
	GATS	2017	80.0%	smoking	4643	37	15-108	58.8	598 (12.9)	1643 (35.4)	2697 (58.1)		16165.34
Botswana	STEPS	2014	63.0%	diabetes, dyslipidemia,	3972	34	15-69	66.8	591 (14.9)	1441 (36.3)	2323 (58.5)	2120	16175.24

				hypertension, obesity, overweight,									
Burkina Faso	DHS	2010	99.2%	statin use obesity, overweight, smoking	40887	33	15-99	52.6	21710 (53.1)	33036 (80.8)	38352 (93.8)	18110	1423.38
Burundi	DHS	2016- 2017	99.7%	obesity, overweight, smoking	40137	30	15-98	52.9	28176 (70.2)	35119 (87.5)	38812 (96.7)	10160	689.01
Cabo Verde	STEPS	2007	99.8%	diabetes, dyslipidemia, hypertension, obesity, overweight, smoking	1742	41	25-64	61.9	146 (8.4)	468 (26.9)	935 (53.7)	524	5768.87
Cameroon	DHS	2011	99.4%	obesity, overweight, smoking	31142	32	15-98	50.8	9155 (29.4)	16256 (52.2)	23449 (75.3)	23298	3352.06
Chad	DHS	2014- 2015	98.9%	obesity, overweight, smoking	44853	30	15-98	51.6	17133 (38.2)	29782 (66.4)	38663 (86.2)	14111	2052.22
Comoros	DHS	2012	96.3%	obesity, overweight, smoking	14087	32	15-99	51.4	2676 (19)	5592 (39.7)	9100 (64.6)	777	2483.41
	STEPS	2011	96.5%	diabetes, hypertension	5172	40	25-64	69.6	977 (18.9)	2048 (39.6)	3341 (64.6)		2465.32
Congo	DHS	2011- 2012	99.8%	obesity, overweight	26370	34	15-99	51.8	10495 (39.8)	16955 (64.3)	22150 (84)	4856	5415.11
Congo Democratic Republic	DHS	2013- 2014	99.9%	obesity, overweight, smoking	45319	31	15-96	51.0	35031 (77.3)	41421 (91.4)	44367 (97.9)	76244	741.17
Cote d'Ivoire	DHS	2011- 2012	98·1%	obesity, overweight	27616	32	15-99	49.6	8284 (30)	16321 (59.1)	22838 (82.7)	23226	2696.19
	GATS	2016	93.4%	smoking	10150	30	15-101	54.4	3004 (29.6)	6891 (67.9)	9104 (89.7)		1617.32
Ethiopia	STEPS	2015	95.5%	diabetes, dyslipidemia, hypertension, statin use	8888	34	18-69	57.7	2737 (30.8)	6123 (68.9)	8016 (90.2)	100835	1518.47
	DHS	2008	97.6%	obesity, overweight	38939	32	15-98	52.7	14212 (36.5)	29749 (76.4)	36758 (94.4)		927.51
Eswatini	STEPS	2014	81.8%	diabetes, dyslipidemia,	3444	34	15-71	64.3	1139 (33.1)	1921 (55.8)	2583 (75)	1104	9309.1

				hypertension, obesity, overweight, smoking, statin use									
Gabon	DHS	2012	99.3%	obesity, overweight	23271	37	15-99	51.6	1000 (4.3)	3281 (14.1)	8610 (37)	1948	16225.39
Gambia	DHS	2013	95.0%	obesity, overweight, smoking	27865	30	15-99	53.2	4541 (16.3)	12399 (44.5)	21177 (76)	2086	1500.51
	STEPS	2010	77.9%	hypertension	3871	36	25-64	54.3	983 (25.4)	2070 (53.5)	3123 (80.7)		1551.59
Ghana	DHS	2014	98.5%	obesity, overweight, smoking	24893	35	15-98	53.0	2962 (11.9)	7467 (30)	14164 (56.9)	27849	3791.28
	SAGE	2008	79.4%	hypertension	5565	60	18-114	48.8	1012 (18.2)	2253 (40.5)	3817 (68.6)		2813.21
Guinea	DHS	2012	99.2%	obesity, overweight, smoking	25184	34	15-98	55.0	9091 (36.1)	17855 (70.9)	23295 (92.5)	11432	2337.95
Kenya	STEPS	2015	95.0%	diabetes, dyslipidemia, hypertension, statin use	4337	36	18-69	58.9	1609 (37.1)	2884 (66.5)	3755 (86.6)	47878	2797.86
	DHS	2014	99.0%	obesity, overweight, smoking	81959	31	15-95	51.3	31554 (38.5)	55240 (67.4)	71796 (87.6)		2713.30
Lesotho	DHS	2014	90.8%	hypertension, obesity, overweight, smoking	18726	34	15-95	53.9	6797 (36.3)	10486 (56)	14419 (77)	2059	2811.24
Liberia	STEPS	2011	87.1%	diabetes, hypertension, obesity, overweight, smoking	1788	35	24-64	53.2	974 (54.5)	1482 (82.9)	1711 (95.7)	4472	1154.41
Madagascar	DHS	2009	98.8%	obesity, overweight, smoking	44648	31	15-99	50.2	34334 (76.9)	40540 (90.8)	43487 (97.4)	24234	1523.02
Malawi	DHS	2015- 2016	99.2%	obesity, overweight, smoking	61989	30	15-98	51.5	42896 (69.2)	55170 (89)	59881 (96.6)	16745	1142.55
wialawi	STEPS	2009	95.5%	diabetes, dyslipidemia, hypertension	4940	36	25-64	65.8	3522 (71.3)	4391 (88.9)	4752 (96.2)	10743	1037.60

	1									1			
Mozambiqu	DHS	2011	99.8%	obesity, overweight, smoking	30998	32	15-98	52.7	20675 (66.7)	26627 (85.9)	29262 (94.4)	27042	984.47
e	STEPS	2005	98.3%	diabetes, dyslipidemia, hypertension	3191	38	25-64	56.7	2390 (74.9)	2907 (91.1)	3085 (96.7)	27042	757.97
Namibia	DHS	2013	96.9%	diabetes, hypertension, obesity, overweight, smoking	24760	33	15-99	52.0	4209 (17)	9111 (36.8)	14137 (57.1)	2315	9599.65
Niger	DHS	2012	98.0%	obesity, overweight, smoking	27968	33	15-99	52.0	13648 (48.8)	22849 (81.7)	26597 (95.1)	20002	859.79
	STEPS	2007	91.3%	diabetes, hypertension	2670	37	15-64	45.8	1933 (72.4)	2419 (90.6)	2584 (96.8)		772.37
Nigeria	DHS	2015	99.4%	obesity, overweight, smoking	99588	33	15-98	50.8	45013 (45.2)	73993 (74.3)	91919 (92.3)	181137	5315.82
Rwanda	DHS	2014- 2015	99.9%	obesity, overweight, smoking	30409	31	15-98	54.0	17302 (56.9)	24570 (80.8)	28006 (92.1)	11369	1671.91
Kwanda	STEPS	2012	99.8%	diabetes, dyslipidemia, hypertension	7002	33	15-64	61.6	4208 (60.1)	5783 (82.6)	6497 (92.8)	11309	1558.62
Sao Tome and Principe	STEPS	2009	95.0%	diabetes, dyslipidemia, hypertension, obesity, overweight, smoking	2376	38	25-64	55.8	814 (34.3)	1696 (71.4)	2200 (92.6)	199	2460.81
	GATS	2015	97.0%	smoking	4347	33	15-100	54.8	1547 (35.6)	2890 (66.5)	3812 (87.7)		3001.82
Senegal	DHS	2010- 2011	98.4%	obesity, overweight	40097	31	15-98	54.8	15437 (38.5)	27426 (68.4)	35445 (88.4)	14578	2775.70
South Africa	DHS	2016	83.4%	diabetes, hypertension, obesity, overweight, smoking	25757	36	15-98	53.6	4662 (18.1)	9452 (36.7)	14526 (56.4)	55386	12214.95
Tanzania	DHS	2015- 2016	98.4%	obesity, overweight, smoking	32731	33	15-95	50.0	16169 (49.4)	25268 (77.2)	30112 (92)	51482	2613.36
	STEPS	2012	94.7%	diabetes,	5537	40	23-65	52.3	2746 (49.6)	4374 (79)	5149 (93)		2362.93

Total			96·3 ⁷ (91.0-		3,269,55	35.0 ⁷ (32.0 -		53.1 ⁷ (51.4-	792,228 ⁹	1,598,609 ⁹	2,346,687 ⁹	3,910,153 ⁹	2696.19 ⁷ (2093.50-
Zimbabwe	DHS	2015	98.8%	obesity, overweight, smoking	23688	32	15-95	53.4	6869 (29.0)	13336 (56.3)	18666 (78.8)	13814	2509.01
Zanzibar	STEPS	2011	91.0%	diabetes, dyslipidemia, hypertension, obesity, overweight, smoking	2391	40	24-64	60.3	1185 (49.6)	1900 (79.5)	2228 (93.2)	404	2329.33
Zambia	STEPS	2017	65.0%	diabetes, dyslipidemia, hypertension, obesity, overweight, statin use	4126	35	18-69	60.9	2430 (58.9)	3168 (76.8)	3729 (90.4)	15879	3717.67
	DHS	2018	99.1%	smoking	32301	31	15-98	51.6	19025 (58.9)	24871 (77.0)	29232 (90.5)		3747.97
Uganda	STEPS	2014	99.0%	diabetes, dyslipidemia, hypertension, statin use	3782	33	18-69	57.6	1456 (38.5)	2586 (68.4)	3301 (87.3)	38225	1722.49
	DHS	2016	98.2%	obesity, overweight, smoking	44343	30	15-98	51.8	17692 (39.9)	30596 (69)	38755 (87.4)		1767.50
Togo	STEPS	2010	91.0%	diabetes, dyslipidemia, hypertension	4204	32	15-64	50.5	2329 (55.4)	3211 (76.4)	3817 (90.8)	7323	1241.92
	DHS	2013- 2014	99.1%	dyslipidemia, hypertension obesity, overweight, smoking	24106	33	15-98	52.4	12559 (52.1)	17983 (74.6)	21888 (90.8)		1379.40

¹Values are unweighted (i.e., do not account for the complex survey design).

²Year(s) in which the data collection for the survey was carried out.

³This includes both the household and the individual response rate.

⁴Poverty levels are in constant 2011 international dollars as provided by the World Bank ^{27,56,57}. ⁵Population in 2015 as estimated by the United Nations, Population Division, Department of Economic and Social Affairs ³⁷. ⁶This is the GDP per capita in constant 2011 international dollars (as estimated by the World Bank ³⁸) for the year in which data were collected for the survey.

⁷This is the median value with each survey having the same weight.

⁸These are interquartile ranges.

⁹This is the sum across all countries.

Abbreviations: CHNS=China Health and Nutrition Survey, DHS=Demographic and Health Surveys, GATS=Global Adult Tobacco Survey, GDP=Gross domestic product, IFLS=Indonesian Family Life Survey, MXFLS=Mexican Family Life Survey, PNC=Pesquisa Nacional de Saude, PPP=purchasing-power-parity-adjusted dollars, SAGE=Study on global AGEing and adult health, SEPHAR=Study for the Evaluation of Prevalence of Hypertension and cardiovascular risk in Romania; STEPS= WHO STEPwise approach to NCD risk factor surveillance; y=years.